Chlorprothixene free base | CAS#113-59-7

MedKoo Cat#: 330145 | Name: Chlorprothixene free base

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Chlorprothixene is a typical antipsychotic drug of the thioxanthene class and was the first of the series to be synthesized. It is a potent, non-selective dopamine, 5-HT and H1 receptor antagonist. Chlorprothixene does also act as FIASMA- functional inhibitor of acid sphingomyelinase.

Chemical Structure

Chlorprothixene free base

CAS#113-59-7 (free base)

Theoretical Analysis

MedKoo Cat#: 330145

Name: Chlorprothixene free base

CAS#: 113-59-7 (free base)

Chemical Formula: C18H18ClNS

Exact Mass: 315.0848

Molecular Weight: 315.86

Elemental Analysis: C, 68.45; H, 5.74; Cl, 11.22; N, 4.43; S, 10.15

Price and Availability

Size	Price	Availability
100mg	USD 350.00	2 Weeks
200mg	USD 650.00	2 Weeks
1g	USD 950.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

6469-93-8 (HCl) 113-59-7 (free base)

Synonym

MK 184; N 714; N 714C; N-714; NSC 1872;0 Paxyl; Rentovet; Ro 4-0403; Taractan; Tarasan; Chlorprothixene free base

IUPAC/Chemical Name

1-Propanamine, 3-(2-chloro-9H-thioxanthen-9-ylidene)-N,N-dimethyl-, (Z)-

InChi Key

WSPOMRSOLSGNFJ-AUWJEWJLSA-N

InChi Code

InChI=1S/C18H18ClNS/c1-20(2)11-5-7-14-15-6-3-4-8-17(15)21-18-10-9-13(19)12-16(14)18/h3-4,6-10,12H,5,11H2,1-2H3/b14-7-

SMILES Code

CN(C)CC/C=C1C2=C(SC3=C\1C=CC=C3)C=CC(Cl)=C2

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 315.86 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Günther KN, Johansen SS, Wicktor P, Banner J, Linnet K. Segmental Analysis of Chlorprothixene and Desmethylchlorprothixene in Postmortem Hair. J Anal Toxicol. 2018 Jun 26. doi: 10.1093/jat/bky038. [Epub ahead of print] PubMed PMID: 29945160. 2: Kim J, Song JH. Thioxanthenes, chlorprothixene and flupentixol inhibit proton currents in BV2 microglial cells. Eur J Pharmacol. 2016 May 15;779:31-7. doi: 10.1016/j.ejphar.2016.03.009. Epub 2016 Mar 3. PubMed PMID: 26945819. 3: Skov L, Johansen SS, Linnet K. Postmortem femoral blood reference concentrations of aripiprazole, chlorprothixene, and quetiapine. J Anal Toxicol. 2015 Jan-Feb;39(1):41-4. doi: 10.1093/jat/bku121. Epub 2014 Oct 22. PubMed PMID: 25342720. 4: Käferstein H, Sticht G, Madea B. Chlorprothixene in bodies after exhumation. Forensic Sci Int. 2013 Jun 10;229(1-3):e30-4. Epub 2013 Apr 28. PubMed PMID: 23821789. 5: Chen YW, Chu CC, Chen YC, Leung YM, Wang JJ. Intrathecal chlorprothixene, cis(z)-flupenthixol, chlorpromazine and fluphenazine for prolonged spinal blockades of sensory and motor functions in rats. Eur J Pharmacol. 2012 Oct 15;693(1-3):31-6. doi: 10.1016/j.ejphar.2012.07.039. Epub 2012 Aug 21. PubMed PMID: 22926199. 6: Santiago LE, García C, Lhiaubet-Vallet V, Miranda MA, Oyola R. Solvent dependence of the photophysical properties of 2-chlorothioxanthone, the principal photoproduct of chlorprothixene. Photochem Photobiol. 2011 May-Jun;87(3):611-7. doi: 10.1111/j.1751-1097.2011.00906.x. Epub 2011 Mar 8. PubMed PMID: 21294748; PubMed Central PMCID: PMC3082582. 7: Piñero LE, García C, Lhiaubet-Vallet V, Oyola R, Miranda MA. Photophysics and photochemistry of z-chlorprothixene in acetonitrile. Photochem Photobiol. 2009 Jul-Aug;85(4):895-900. PubMed PMID: 19708200. 8: Bader W, Greiner C, Haen E. Increase of risperidone concentration under chlorprothixene comedication--a case report. Pharmacopsychiatry. 2008 May;41(3):116-7. doi: 10.1055/s-2007-1004590. PubMed PMID: 18484554. 9: Huang F, Jin G, Liu Y, Kong J. Sensitive determination of phenylephrine and chlorprothixene at poly(4-aminobenzene sulfonic acid) modified glassy carbon electrode. Talanta. 2008 Feb 15;74(5):1435-41. doi: 10.1016/j.talanta.2007.09.018. Epub 2007 Sep 29. PubMed PMID: 18371801. 10: Misiuk W. Sensitive spectrophotometric methods for quantitative determination of chlorprothixene in pharmaceutical dosage form. Pak J Pharm Sci. 2006 Apr;19(2):87-94. PubMed PMID: 16751116. 11: Karpińska J, Szostak J. Determination of chlorprothixene and amitryptyline hydrochlorides by UV-derivative spectrophotometry and UV-solid-phase spectrophotometry. Spectrochim Acta A Mol Biomol Spectrosc. 2005 Mar;61(5):975-81. PubMed PMID: 15683805. 12: Meyer S, Gottschling S, Georg T, Lothschütz D, Graf N, Sitzmann FC. Gamma-hydroxybutyrate versus chlorprothixene/phenobarbital sedation in children undergoing MRI studies. Klin Padiatr. 2003 Mar-Apr;215(2):69-73. PubMed PMID: 12677545. 13: Bagli M, Süverkrüp R, Quadflieg R, Höflich G, Kasper S, Möller HJ, Langer M, Barlage U, Rao ML. Pharmacokinetic-pharmacodynamic modeling of tolerance to the prolactin-secreting effect of chlorprothixene after different modes of drug administration. J Pharmacol Exp Ther. 1999 Nov;291(2):547-54. PubMed PMID: 10525070. 14: Lepp U, Schlaak M, Schulz KH. Contact dermatitis to chlorprothixene. Allergy. 1998 Jul;53(7):718-9. PubMed PMID: 9700045. 15: Bagli M, Süverkrüp R, Rao ML, Bode H. Mean input times of three oral chlorprothixene formulations assessed by an enhanced least-squares deconvolution method. J Pharm Sci. 1996 Apr;85(4):434-9. PubMed PMID: 8901084. 16: Bagli M, Rao ML, Höflich G, Kasper S, Langer M, Barlage U, Beneke M, Süverkrüp R, Möller HJ. Pharmacokinetics of chlorprothixene after single intravenous and oral administration of three galenic preparations. Arzneimittelforschung. 1996 Mar;46(3):247-50. PubMed PMID: 8901143. 17: Duignan GM, Miller JH, Skellern GG. Development of a liquid chromatographic method for the control of related substances in chlorprothixene hydrochloride. J Pharm Biomed Anal. 1996 Feb;14(4):451-6. PubMed PMID: 8729644. 18: Bagli M, Rao ML, Höflich G. Quantification of chlorprothixene, levomepromazine and promethazine in human serum using high-performance liquid chromatography with coulometric electrochemical detection. J Chromatogr B Biomed Appl. 1994 Jul 1;657(1):141-48. PubMed PMID: 7952060. 19: Delbeke FT, Teale P, Debackere M, Houghton E. ELISA screening with GC-MS confirmation of the tranquilizer chlorprothixene administered in subtherapeutic doses to horses. J Pharm Biomed Anal. 1993 Jul;11(7):569-75. PubMed PMID: 8399531. 20: Luisto M. Polyneuropathy caused by chlorprothixene. Acta Psychiatr Scand. 1992 Mar;85(3):246-8. PubMed PMID: 1314010.